Week in Review: Sinovac's Privatization Offer Draws $459 Million Outside Bid

01:04 EDT 2 Jul 2017 | ChinaBio Today

Deals and Financings

--Shandong Sinobioway offered $459 million to acquire Beijing vaccine maker Sinovac, a 14% premium to management's earlier privatization bid;
--AGIC Capital of Hong Kong will acquire Ritedose Corporation, a US formulation/blow-fill-seal company, for approximately $700 million;
--Guangzhou broke ground on a major new $800 million biopharma park partnered with General Electric;
--CSPC Pharma of Hong Kong acquired global rights to two pre-clinical drug candidates from University of Texas institutions in a $114 million deal;
--Vivace Therapeutics, a Bay-area oncology company, raised $40 million in two venture rounds from China-US investors;
--Zai Lab, a Shanghai novel drug development/in-licensing company, closed a $30 million Series C round;
--iCarbonX, a China big data/AI startup, participated in a $8.4 million series B funding of HealthLoop, a California company that facilitates patient-doctor contact;--India's Biological E. Limited in-licensed rights to two Takeda vaccines for India, China and low/middle income countries;

Trials and Approvals

--Hutchison China MediTech (Chi-Med) and AstraZeneca announced the start of a global Phase III trial of their partnered drug, the c-MET inhibitor savolitinib, for US-Europe approvals. More details....

Stock Symbols: (SZE: 002581) (NSDQ: SVA) (NYSE: GE) (HK: 1093) (TSE: 4502) (AIM/NSDQ: HCM) (NYSE: AZN)

Share this with colleagues:  

Original Article: Week in Review: Sinovac's Privatization Offer Draws $459 Million Outside Bid


More From BioPortfolio on "Week in Review: Sinovac's Privatization Offer Draws $459 Million Outside Bid"

Quick Search


Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...